10:09 AM EST - Angiotech Pharmaceuticals Inc. : is packaging its assets not related to the Taxus coronary stent into a new subsidiary, Angiotech Pharmaceutical Interventions Inc. Private equity firms Ares Management and New Leaf Venture Partners will invest between $200 million and $300 million in the new enterprise. Angiotech Pharmaceuticals Inc.
shares T.ANP are trading off 3 cents at $2.90.
